In April 2025, Abbott submitted paperwork to the FDA for something that would’ve seemed like science fiction a decade ago: an insulin pump built by Medtronic, designed specifically to talk to Abbott’s FreeStyle Libre continuous glucose monitor. Two competitors, one device ecosystem, one patient outcome. That’s biotech medtech collaboration in the most literal sense, and it’s becoming the dominant model in healthcare innovation.
These aren’t just partnership press releases anymore. They’re structural shifts in how medicine gets built.
What Is Biotech & MedTech Collaboration, Really?
Biotech medtech collaboration refers to formal or informal working relationships between biotechnology companies, focused on biological therapies, drug development, and genomics, and medical technology companies, which build devices, diagnostics, and hardware. The goal is usually a product or system that neither could build alone: a drug that needs a delivery device, a diagnostic that needs a biological marker, or a treatment protocol that needs real-time data.
These partnerships can take many forms: licensing agreements, co-development deals, joint ventures, or full acquisitions. What they share is the recognition that biology and engineering are no longer separate disciplines.
Why Biotech and MedTech Companies Are Joining Forces Now
The honest answer? Neither side can afford not to.
Biotech companies are sitting on extraordinary science: CRISPR therapies, mRNA platforms, AI-designed antibodies, but they often lack the device infrastructure to deliver or monitor those treatments in the real world. MedTech companies, meanwhile, have precision hardware and vast patient data streams but increasingly need biological intelligence to make those devices smarter and more clinically relevant.
The global biotech market is now estimated at $1.744 trillion in 2025, projected to surpass $5 trillion by 2034. That scale creates pressure to move fast. And moving fast, in medicine, almost always means finding a partner who fills your blind spots.
There’s also the AI factor. The proportion of total deal value accounted for by up-front payments for AI-based target and drug discovery collaborations rose by 9% to 27% in 2025 compared to 2024, with total amounts paid up-front approaching $800 million out of a combined deal value of $29.7 billion. AI is pulling biotech and medtech together in ways that traditional R&D structures simply weren’t built for.
Precision medicine partnerships are especially driving this. Key market players are focusing on strategic alliances to strengthen their footprints in precision medicine, a field that fundamentally requires both biological insight and device-level measurement.
Where Biotech MedTech Collaboration Is Happening Today
If you want to understand where biotech medtech collaboration is actually concentrated, look at three areas: drug delivery, diagnostics, and data.
Smart Drug Delivery and Connected Devices
Drug-device combination products are the most visible output of these partnerships. Integration of IoT and AI now enables real-time monitoring, dose adjustment, and improved patient adherence, while continuous glucose monitors, wearable injectors, and connected inhalers are transforming chronic disease management.
The Abbott-Medtronic case isn’t isolated. It represents a broader convergence where device makers are building platforms, not products. The goal isn’t just to deliver a drug; it’s to close the loop between administration, physiological response, and real-world adjustment.
In June 2024, Abbott received FDA clearance for Libre Rio, its first over-the-counter continuous glucose monitoring system for adults with Type 2 diabetes who don’t use insulin, a wearable biosensor enabling continuous glucose tracking without a prescription, expanding access to metabolic monitoring and supporting preventive health applications. That’s a biotech insight (glucose biomarker science) delivered through MedTech infrastructure (hardware, sensors, connectivity).
AI-Powered Diagnostics and Real-World Data
The collaboration isn’t just physical; it’s computational. AI-enabled platforms are being used to analyze real-time patient data from wearable technology to personalize treatment plans. That requires both the device to collect the data and the biological model to interpret it.
AI-backed companies in clinical trials are reporting 20–30% improvements in success rates, along with 50% shorter trial durations. When wearable diagnostics feed that AI pipeline directly, the loop tightens further. Decentralized clinical trials, where patients wear monitors at home rather than sitting in hospitals, are becoming one of the clearest expressions of biotech medtech collaboration in action.
What Makes These Partnerships So Hard to Get Right
Here’s where optimism gets complicated.
Biotech medtech collaboration sounds straightforward on paper. In practice, it runs into three walls almost immediately: IP, regulation, and culture.
On IP: when a biotech firm’s molecule and a medtech firm’s device are combined into a single product, who owns the outcome data? Who owns the improvements discovered during joint development? For MedTech companies, securing intellectual property is only part of the challenge; bringing a medical device to market involves navigating complex regulatory landscapes that vary significantly across different jurisdictions. Add a biotech partner into that equation, and the compliance surface doubles.
On regulation: combination products, which integrate drugs, devices, and sometimes biologics, fall into a special FDA category that requires coordination across multiple review divisions. The high costs of development, complex regulatory pathways, and intense market competition create substantial barriers to attracting investors to medtech partnerships specifically. Only about 5% of venture capital in healthcare flows to medical device companies, per a Deloitte report. That number doesn’t get better when regulatory timelines stretch.
And then there’s culture. Biotech companies tend to think in terms of molecules, mechanisms, and trial endpoints. MedTech companies think in engineering tolerances, form factors, and manufacturing scale. Getting those two worldviews to agree on what “done” looks like for a product that has to satisfy both the FDA’s drug and device divisions is harder than it sounds.
The companies that navigate this well tend to do one thing differently: they involve regulatory strategy from day one, not as a checkpoint but as a design constraint.
What the Future of Biotech MedTech Collaboration Looks Like
The trajectory is clear, even if the timeline isn’t.
AI’s role in biopharma will expand exponentially when combined with emerging technologies like synthetic biology and quantum computing, together holding the potential to solve long-standing challenges like drug resistance and the inefficiencies of traditional R&D methods. When you add medtech’s hardware layer to that equation, you get something genuinely new: closed-loop therapeutic systems that detect, decide, and deliver without waiting for a physician’s manual input.
The Novartis-Monte Rosa deal, where Novartis pledged a potential $5.76 billion to a clinical-stage biotech to develop novel molecular glue degraders using an AI/machine learning-enabled platform targeting traditionally undruggable immune-mediated disease targets, illustrates what’s at stake. These aren’t small experiments. They’re bets on an entirely different model of drug development, one that increasingly requires device-level feedback to work.
Biotech medtech collaboration won’t be a differentiator for long. It will be the baseline. The companies building those cross-disciplinary capabilities now- not just the partnerships, but the internal structures to make them work- are the ones positioning for the next decade of medicine.
The question isn’t whether biotech and medtech will converge. It’s whether any company can afford to develop the next generation of therapies without converging first.
